The Ki-67 labeling index (LI) was highest in ER(-)/HER2(-) (36.5%), and decreased in order from ER(-)/HER2(+) (31.4%), ER(+)/HER2(+) (17.7%), to (ER(+)/HER2(-) (15.9%) (p=0.001).     ///    and iv) ER(-)/HER2(-) (19.0%).     ///    Breast cancer specimens (n=58) were categorized into four groups: i) ER(+)/HER2(-) (51.7%).     ///    ii) ER(+)/HER2(+) (8.6%).     ///    "ER(-)/HER2(-) breast cancers have potential in the development of novel therapeutics, including targeted medicines.. "    ///    "EGFR, p53 and vimentin were highly expressed in ER(-)/HER2(-) breast cancer cells (p<0.01). "    ///    iii) ER(-)/HER2(+) (20.7%).     ///    "The purpose of present study is to examine ER(-)/HER2(-) breast cancers, with a particular focus on epidermal growth factor receptor (EGFR). "    ///    "Overall, the ER(-)/HER2(-) breast cancer showed the highest Ki-67 LI, the most frequent expression of EGFR, p53 and vimentin, as well as the lowest expression of cyclinD1. "